IgM-MM is Predominantly a Pre-Germinal Center Disorder and has a distinct genomic and transcriptomic signature from WM.

Abstract IgM multiple myeloma (MM) is a rare disease subgroup. Its differentiation from other IgM-producing gammopathies such as Waldenstrom’s macroglobulinemia (WM) has not been well characterized but is essential for proper risk assessment and treatment. In this study, we investigated genomic and transcriptomic characteristics of IgM-MM samples using whole genome and transcriptome sequencing to identify differentiating characteristics from non-IgM-MM and WM. Our results suggest that IgM-MM shares most of its defining structural variants and gene-expression profiling with MM, but has some key characteristics including t(11;14) translocation, chromosome 6 and 13 deletion as well as distinct molecular and transcription-factor signatures. Furthermore, IgM-MM translocations were predominantly characterized by VHDHJH-recombination induced breakpoints, as opposed to the usual class-switching region breakpoints; coupled with its lack of class-switching, this data favors a pre-germinal center origin. Finally, we found elevated expression of clinically relevant targets including CD20 and BTK, as well as high BCL2/BCL2L1 ratio in IgM-MM, providing potential for targeted therapeutics.